Drug Profile


Alternative Names: E5; Promune-E5; Xomen-E5

Latest Information Update: 18 Aug 2009

Price : $50

At a glance

  • Originator XOMA
  • Class Antitoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Gram-negative infections; Septic shock

Most Recent Events

  • 28 Jun 1999 Discontinued-preregistration for Septic shock in European Union (IV)
  • 28 Jun 1999 Discontinued-preregistration for Septic shock in Japan (IV)
  • 04 Aug 1997 Discontinued-preregistration for Septic shock in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top